TCG Crossover Management, LLC
Reported holdings as of Q2 2026, from 19 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ABIVAX SA | ABVX | $800.6M | 6,007,834 | -1.40pp | 11q | -7.3%-$63.1M | |
| TANGO THERAPEUTICS INC | TNGX | $283.9M | 9,081,201 | +0.52pp | 7q | -13.8%-$45.3M | |
| CG ONCOLOGY INC | CGON | $260.8M | 3,670,206 | -0.84pp | 10q | HELD | |
| COGENT BIOSCIENCES INC | COGT | $187.9M | 4,854,436 | -0.93pp | 19q | -1.9%-$3.6M | |
| IMMUNOVANT INC | IMVT | $171.8M | 4,457,988 | +0.96pp | 3q | HELD | |
| SPYRE THERAPEUTICS INC | SYRE | $168.7M | 1,900,582 | +1.31pp | 4q | HELD | |
| DIANTHUS THERAPEUTICS INC | DNTH | $163.4M | 1,676,624 | -0.10pp | 7q | HELD | |
| MIRUM PHARMACEUTICALS INC | MIRM | $124.3M | 1,062,049 | +0.18pp | 3q | HELD | |
| ZAI LAB LTD | ZLAB | $116.6M | 6,137,627 | - | new | NEW | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $112.1M | 6,243,812 | +0.21pp | 8q | HELD | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $111.9M | 4,622,151 | +0.51pp | 3q | HELD | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $110.2M | 11,020,968 | -0.35pp | 2q | HELD | |
| VOR BIOPHARMA INC | VOR | $104.4M | 5,673,078 | -0.25pp | 2q | HELD | |
| TYRA BIOSCIENCES INC | TYRA | $103.8M | 3,248,980 | -1.07pp | 19q | HELD | |
| DYNE THERAPEUTICS INC | DYN | $102.5M | 4,615,144 | +0.07pp | 14q | HELD | |
| DISC MEDICINE INC | IRON | $98.1M | 1,341,862 | -0.10pp | 2q | HELD | |
| RELAY THERAPEUTICS INC | RLAY | $80.0M | 4,273,356 | +0.71pp | 4q | HELD | |
| SAVARA INC | SVRA | $76.2M | 12,362,205 | -0.10pp | 12q | HELD | |
| AURA BIOSCIENCES INC | AURA | $67.7M | 9,533,333 | - | new | NEW | |
| REVOLUTION MEDICINES INC | RVMD | $63.8M | 340,899 | -0.07pp | 4q | -40.9%-$44.1M | |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $58.3M | 2,895,304 | - | new | NEW | |
| KODIAK SCIENCES INC | KOD | $56.3M | 1,445,538 | -0.22pp | 11q | HELD | |
| AVALO THERAPEUTICS INC | AVTX | $55.8M | 3,017,120 | +1.02pp | 8q | +308.6%+$42.1M | |
| LB PHARMACEUTICALS INC | LBRX | $47.0M | 1,447,310 | -0.17pp | 4q | -21.3%-$12.7M | |
| CENTURY THERAPEUTICS INC | IPSC | $43.4M | 17,754,430 | -0.07pp | 2q | HELD | |
| TECTONIC THERAPEUTIC INC | TECX | $41.4M | 1,204,891 | -0.07pp | 2q | HELD | |
| XENCOR INC | XNCR | $39.5M | 2,452,138 | +0.10pp | 8q | HELD | |
| SURROZEN INC | SRZN | $38.2M | 1,473,101 | -0.31pp | 2q | HELD | |
| EDITAS MEDICINE INC | EDIT | $36.0M | 11,111,111 | - | new | NEW | |
| MBX BIOSCIENCES INC | MBX | $35.9M | 650,000 | +0.31pp | 8q | HELD | |
| PHARVARIS N V | PHVS | $34.9M | 1,008,229 | - | new | NEW | |
| SILENCE THERAPEUTICS PLC | SLN | $33.3M | 3,033,560 | +0.34pp | 16q | HELD | |
| INFLARX NV | IFRX | $32.5M | 14,500,000 | - | new | NEW | |
| ALTIMMUNE INC | ALT | $30.4M | 10,000,000 | - | new | NEW | |
| JANUX THERAPEUTICS INC | JANX | $27.5M | 1,789,617 | -0.05pp | 3q | HELD | |
| PERSPECTIVE THERAPEUTICS INC | CATX | $27.0M | 7,915,567 | -0.30pp | 2q | HELD | |
| AGOMAB THERAPEUTICS NV | AGMB | $26.7M | 2,053,233 | +0.02pp | 2q | HELD | |
| BIOHAVEN LTD | BHVN | $26.5M | 1,779,952 | -0.48pp | 3q | -61.6%-$42.4M | |
| AKTIS ONCOLOGY INC | AKTS | $22.5M | 696,560 | - | new | NEW | |
| ALECTOR INC | ALEC | $20.1M | 10,000,000 | -0.13pp | 3q | HELD | |
| FORTE BIOSCIENCES INC | FBRX | $19.6M | 920,000 | - | new | NEW | |
| MONOPAR THERAPEUTICS INC | MNPR | $18.8M | 203,327 | +0.25pp | 4q | +53.9%+$6.6M | |
| OCULAR THERAPEUTIX INC | OCUL | $16.2M | 1,647,752 | -0.01pp | 10q | HELD | |
| ADC THERAPEUTICS SA | ADCT | $12.2M | 11,390,175 | -0.93pp | 4q | HELD | |
| ALX ONCOLOGY HLDGS INC | ALXO | $11.7M | 5,655,487 | -0.46pp | 2q | -56.5%-$15.2M | |
| ENTRADA THERAPEUTICS INC | TRDA | $7.8M | 1,060,230 | -0.64pp | 19q | -53.7%-$9.0M | |
| CULLINAN THERAPEUTICS INC | CGEM | $7.4M | 406,786 | +0.01pp | 2q | HELD | |
| ARVINAS INC | ARVN | $5.9M | 707,098 | -0.58pp | 4q | -70.4%-$14.0M | |
| KORRO BIO INC | KRRO | $5.5M | 416,301 | flat | 4q | HELD | |
| RESEARCH ALLIANCE CORP III | RACC | $5.3M | 500,000 | - | new | NEW | |
| LEONABIO INC | LONA | $4.3M | 464,398 | -0.03pp | 3q | HELD | |
| JATT II ACQUISITION CORP | $2.3M | 200,000 | - | new | NEW | ||
| CONTEXT THERAPEUTICS INC | CNTX | $1.5M | 2,682,696 | -0.17pp | 2q | HELD | |
| EIKON THERAPEUTICS INC | EIKN | $494.6K | 37,902 | - | new | NEW |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $4.1B | 98.4% |
| Not classified | $65.9M | 1.6% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $4.2B | 54 | 12 | 2 | 9 | 7 | 57.4% | 45 |
| Q1 2026 | $3.5B | 49 | 11 | 8 | 10 | 5 | 60.9% | 45 |
| Q4 2025 | $3.0B | 43 | 8 | 9 | 6 | 5 | 64.3% | 48 |
| Q3 2025 | $2.0B | 40 | 11 | 7 | 5 | 8 | 65.9% | 48 |
| Q2 2025 | $875.5M | 37 | 5 | 1 | 3 | 5 | 56.3% | 45 |
| Q1 2025 | $733.1M | 37 | 0 | 2 | 2 | 1 | 55.3% | 44 |
| Q4 2024 | $1.0B | 38 | 5 | 4 | 2 | 3 | 52.0% | 45 |
| Q3 2024 | $1.2B | 36 | 9 | 2 | 4 | 5 | 58.4% | 45 |
| Q2 2024 | $959.5M | 32 | 2 | 6 | 4 | 3 | 64.7% | 45 |
| Q1 2024 | $1.3B | 33 | 9 | 5 | 7 | 5 | 58.3% | 45 |
| Q4 2023 | $901.7M | 29 | 5 | 2 | 1 | 2 | 61.3% | 45 |
| Q3 2023 | $679.1M | 26 | 8 | 3 | 2 | 4 | 61.8% | 45 |
| Q2 2023 | $609.8M | 22 | 2 | 4 | 1 | 2 | 80.7% | 45 |
| Q1 2023 | $513.0M | 22 | 3 | 3 | 5 | 2 | 78.0% | 45 |
| Q4 2022 | $566.6M | 21 | 5 | 7 | 4 | 5 | 79.5% | 45 |
| Q3 2022 | $333.4M | 21 | 3 | 4 | 5 | 4 | 83.4% | 45 |
| Q2 2022 | $235.4M | 22 | 2 | 4 | 4 | 0 | 80.2% | 46 |
| Q1 2022 | $249.1M | 20 | 5 | 7 | 2 | 0 | 78.8% | 46 |
| Q4 2021 | $213.6M | 15 | 0 | 0 | 0 | 0 | 83.5% | 49 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.